Oxidative stress and therapeutic implications in psychiatric disorders

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 46, Issue , 2013, Pages 197-199

  Zhang, Xiang Yang ^a,b,c   Yao, Jeffrey K ^d,e,f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c PEKING UNIVERSITY   (China)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antioxidant defense system; Antioxidant therapy; Bipolar disorders; Major depression; Schizophrenia; Tardive dyskinesia

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ASCORBIC ACID; CATALASE; DOCOSAHEXAENOIC ACID; DOPAMINE; GLUTATHIONE PEROXIDASE; ICOSATRIENOIC ACID; MANGANESE SUPEROXIDE DISMUTASE; NEUROLEPTIC AGENT; SUPEROXIDE DISMUTASE;

ADD ON THERAPY; ARTICLE; BIPOLAR DISORDER; DEPRESSION; DNA POLYMORPHISM; DOPAMINE METABOLISM; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; HUMAN; LIPID PEROXIDATION; MAJOR DEPRESSION; MENTAL DISEASE; NITROSATIVE STRESS; OXIDATIVE STRESS; PATHOGENESIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT DURATION; VITAMIN SUPPLEMENTATION;

ANTIOXIDANT DEFENSE SYSTEM; ANTIOXIDANT THERAPY; AODS; BIPOLAR DISORDERS; BPRS; BRIEF PSYCHIATRIC RATING SCALE; CAT; CATALASE; DEHYDROASCORBIC ACID; DHA; EICOSAPENTAENOIC ACID; EPA; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE S-TRANSFERASES; GSH; GSHPX; GST; MAJOR DEPRESSION; N-ACETYL-CYSTEINE; NAC; NADPH; NITRIC OXIDE; NO; PANSS; POSITIVE AND NEGATIVE SYNDROME SCALE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RNS; ROS; SCHIZOPHRENIA; SOD; SUPEROXIDE DISMUTASE; TARDIVE DYSKINESIA; TD;

ANTIOXIDANTS; FREE RADICAL SCAVENGERS; HUMANS; LIPID PEROXIDATION; MENTAL DISORDERS; OXIDATIVE STRESS;

EID: 84883560286     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.03.003     Document Type: Article

References (29)

1. Andreazza A.C., Kauer-Sant'anna M., Frey B.N., Bond D.J., Kapczinski F., Young L.T., et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008, 111:135-144.
2. Berk M., Dean O., Cotton S.M., Gam C.S., Kapczinski F., Fernandes B.S., et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 2011, 135:389-394.
3. Boskovic M., Vovk T., Kores Plesnicar B., Grabnar I. Oxidative stress in schizophrenia. Curr Neuropharmacol. 2011, 9:301-312.
4. Cho C.H., Lee H.J. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Prog Neuropsychopharmacol Biol Psychiatry 2013, 46:207-213.
5. Correll C.U., Schenk E.M. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008, 21(2):151-156.
6. Dean O.M., van den Buuse M., Berk M., Copolov D.L., Mavros C., Bush A.I. N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and D-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder. Neurosci Lett 2011, 499:149-153.
7. Elkashef A.M., Wyatt R.J. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophr Bull 1999, 25:731-740.
8. Hoffer A., Osmond H., Smythies J. Schizophrenia: a new approach. II. Result of a year's research. J Ment Sci 1954, 100:29-45.
9. Horrobin D.F., Glen A.I.M., Hudson C.J. Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders: the relationship between dyslexia and schizophrenia. Med Hypotheses 1995, 45:605-613.
10. Lohr J.B., Browning J.A. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull 1995, 31:159-165.
11. Lohr J.B., Kuczenski R., Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003, 17:47-62.
12. Machado-Vieira R., Andreazza A.C., Viale C.I., Zanatto V., Cereser V., da Silva Vargas R., et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007, 421:33-36.
13. Maes M., Galecki P., Chang Y.S., Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:676-692.
14. Magalhaes P.V., Dean O.M., Bush A.I., Copolov D.L., Malhi G.S., Kohlmann K., et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr 2011, 33:374-378.
15. Mahadik S.P., Yao J.K. Phospholipids in schizophrenia. Textbook of Schizophrenia 2006, 117-135. The American Psychiatric Publishing, Washington, DC. J.A. Lieberman, T.S. Stroup, D.O. Perkins (Eds.).
16. Marazziti D., Baroni S., Picchetti M., Landi P., Silvestri S., Vatteroni E., et al. Psychiatric disorders and mitochondrial dysfunctions. Eur Rev Med Pharmacol Sci 2012, 16:270-275.
17. Pae C.U., Yu H.S., Kim T.S., Lee C.U., Lee S.J., Jun T.Y., et al. Monocyte chemoattractant protein-1 (MCP1) promoter-2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. Psychiatry Res 2004, 127:279-281.
18. Pae C.U., Marks D.M., Han C., Patkar A.A., Steffens D. Does neurotropin-3 have a therapeutic implication in major depression?. Int J Neurosci 2008, 118:1515-1522.
19. Pae C.U., Lee S.Y., Lee S.J., Han C., Patkar A., Masand P. Oxidative/nitrosative stress and antidepressants: targets for novel antidepressants. Prog Neuro-psychopharmacol Biol Psychiatry 2013, 46:224-235.
20. Pandya C.D., Howell K.R., Pillai A. Antioxidants as potential therapeutics for neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2013, 46:214-223.
21. Pillai A, Yao JK. Antioxidant interventions in neuropsychiatric disorders. In: Dietrich-Muszalska A., editor. Oxidative and nitrative stress in psychiatric disorders. New York, NY: Springer; in press.
22. Sarris J., Mischoulon D., Schweitzer I. Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials. Bipolar Disord 2011, 13:454-465.
23. Savas H.A., Gergerlioglu H.S., Armutcu F., Herken H., Yilmaz H.R., Kocoglu E., et al. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry 2006, 7:51-55.
24. Singh V., Singh S.P., Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int J Neuropsychopharmacol 2010, 13:257-271.
25. Skolnick P. Beyond monoamine-based therapies: clues to new approaches. J Clin Psychiatry 2002, 63(Suppl. 2):19-23.
26. Skosnik P.D., Yao J.K. From phospholipid and fatty acid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia?. Prostaglands Leukot Essent Fatty Acids 2003, 69:367-384.
27. Wu J.Q., Kosten T.R., Zhang X.Y. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 46:200-206.
28. Yao J.K., Keshavan M.S. Antioxidants, redox signaling, and pathophysiology of schizophrenia: an integrative view. Antioxid Redox Signal 2011, 15:2011-2035.
29. Yao JK, Reddy RD, Condray R, Long T, Haas G. Pathological and therapeutic implications of omega-3 fatty acids in schizophrenia. In: McNamara R.K., editor. The omega-3 fatty acid deficiency syndrome: opportunities for disease prevention. Hauppauge, NY: Nova Science Publishers, Inc.; in press.